[go: up one dir, main page]

CY1109693T1 - ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΙΜΙΔΑΖΟΛΙΑ ΩΣ ΑΝΑΣΤΟΛΕΙΣ TAFIa - Google Patents

ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΙΜΙΔΑΖΟΛΙΑ ΩΣ ΑΝΑΣΤΟΛΕΙΣ TAFIa

Info

Publication number
CY1109693T1
CY1109693T1 CY20091101349T CY091101349T CY1109693T1 CY 1109693 T1 CY1109693 T1 CY 1109693T1 CY 20091101349 T CY20091101349 T CY 20091101349T CY 091101349 T CY091101349 T CY 091101349T CY 1109693 T1 CY1109693 T1 CY 1109693T1
Authority
CY
Cyprus
Prior art keywords
tafia
suspensions
substituted imidazoles
compounds
conditions
Prior art date
Application number
CY20091101349T
Other languages
English (en)
Inventor
Charlotte Moira Norfor Allerton
Julian Blagg
Mark Edward Bunnage
John Steele
Original Assignee
Pfizer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0020346A external-priority patent/GB0020346D0/en
Priority claimed from GB0027409A external-priority patent/GB0027409D0/en
Priority claimed from GB0029556A external-priority patent/GB0029556D0/en
Application filed by Pfizer Limited filed Critical Pfizer Limited
Publication of CY1109693T1 publication Critical patent/CY1109693T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ενώσεις του τύπου (I). Αυτές οι ενώσεις είναι μια κατηγορία αναστολέων TAFIa, αθηροσκλήρωσης, συμφύσεων, δερματικής ουλής, καρκίνου, ινωτικών καταστάσεων, φλεγμονωδών ασθενειών και αυτών των καταστάσεων οι οποίες ευεργετούνται από διατήρηση ή ενίσχυση επιπέδων βραδυκινίνης στο σώμα.
CY20091101349T 2000-08-17 2009-12-30 ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΙΜΙΔΑΖΟΛΙΑ ΩΣ ΑΝΑΣΤΟΛΕΙΣ TAFIa CY1109693T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0020346A GB0020346D0 (en) 2000-08-17 2000-08-17 Pharmaceuticals
GB0027409A GB0027409D0 (en) 2000-11-09 2000-11-09 Pharmaceuticals
GB0029556A GB0029556D0 (en) 2000-12-04 2000-12-04 Pharmaceuticals
EP01954264A EP1311488B1 (en) 2000-08-17 2001-08-08 Substituted imidazoles as tafia inhibitors

Publications (1)

Publication Number Publication Date
CY1109693T1 true CY1109693T1 (el) 2014-08-13

Family

ID=27255849

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091101349T CY1109693T1 (el) 2000-08-17 2009-12-30 ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΙΜΙΔΑΖΟΛΙΑ ΩΣ ΑΝΑΣΤΟΛΕΙΣ TAFIa

Country Status (38)

Country Link
EP (1) EP1311488B1 (el)
JP (2) JP4119746B2 (el)
KR (1) KR20030022412A (el)
CN (1) CN1443173A (el)
AP (1) AP1375A (el)
AR (1) AR035580A1 (el)
AT (1) ATE447557T1 (el)
AU (1) AU2001276605A1 (el)
BG (1) BG107330A (el)
BR (1) BR0113289A (el)
CA (1) CA2419633C (el)
CY (1) CY1109693T1 (el)
CZ (1) CZ2003388A3 (el)
DE (1) DE60140368D1 (el)
DK (1) DK1311488T3 (el)
DO (1) DOP2001000233A (el)
EA (1) EA005532B1 (el)
EE (1) EE200300070A (el)
ES (1) ES2334101T3 (el)
HR (1) HRP20030103A2 (el)
HU (1) HUP0303763A3 (el)
IL (1) IL153225A0 (el)
IS (1) IS6638A (el)
MA (1) MA26940A1 (el)
MX (1) MXPA03001425A (el)
NO (1) NO20030706L (el)
NZ (1) NZ522823A (el)
OA (1) OA12362A (el)
PA (1) PA8525401A1 (el)
PE (1) PE20020352A1 (el)
PL (1) PL361054A1 (el)
PT (1) PT1311488E (el)
SI (1) SI1311488T1 (el)
SK (1) SK1732003A3 (el)
SV (1) SV2002000602A (el)
TN (1) TNSN01126A1 (el)
UY (1) UY26889A1 (el)
WO (1) WO2002014285A1 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103272D0 (sv) 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
US6713496B2 (en) 2002-01-22 2004-03-30 Pfizer Inc 3-(imidazolyl)-2-alkoxypropanoic acids
IL162677A0 (en) * 2002-01-22 2005-11-20 Pfizer 3-(Imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
MXPA04005940A (es) 2002-01-22 2004-09-13 Pfizer Acidos 3-(imidazolil)-2-aminopropanoicos.
AU2004235488A1 (en) * 2003-04-29 2004-11-11 Universitat Zurich Nepsilon and/or nalpha derivatized, metal and organic protected l-histidine for coupling to biomolecules for highly efficient labeling with [M(OH2)3(CO)3]+ by fac coordination
SE0302853D0 (sv) * 2003-10-29 2003-10-29 Astrazeneca Ab Chemical compounds
AU2004290499C1 (en) * 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
WO2005051384A1 (en) * 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
CA2604912A1 (en) * 2005-04-18 2006-10-26 Bayer Schering Pharma Aktiengesellschaft Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci
DE102005049385A1 (de) * 2005-10-15 2007-04-19 Sanofi-Aventis Deutschland Gmbh Imidazolderivate als Inhibitoren von TAFIa
HRP20150514T1 (hr) * 2006-12-06 2015-09-11 Sanofi DERIVATI SULFAMIDA KAO INHIBITORI TAFIa
EP2262783A2 (en) * 2008-02-21 2010-12-22 Sanofi-Aventis Covalently binding imaging probes
JPWO2010050525A1 (ja) 2008-10-29 2012-03-29 大正製薬株式会社 ＴＡＦＩａ阻害活性を有する化合物
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2548872B1 (en) 2010-03-18 2016-09-28 Daiichi Sankyo Company, Limited Cyclopropanecarboxylic acid derivative
ES2643132T3 (es) * 2010-03-18 2017-11-21 Daiichi Sankyo Company, Limited Derivado de imidazol cicloalquilo sustituido
GEP201706614B (en) * 2011-05-17 2017-02-10 Pharmasyntez Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
JP5996647B2 (ja) * 2011-07-22 2016-09-21 カンブレックス カルルスクーガ アクチ ボラケットＣａｍｂｒｅｘ Ｋａｒｌｓｋｏｇａ Ａｂ ４−置換イミダゾールの新規な調製プロセス
WO2013039202A1 (ja) * 2011-09-15 2013-03-21 第一三共株式会社 新規アクリル酸誘導体
BR112015029667A2 (pt) 2013-06-10 2017-07-25 Sanofi Sa derivados de ureia macrocíclica como inibidores de tafia, sua preparação e seus usos como produtos farmacêuticos
WO2017062468A1 (en) 2015-10-07 2017-04-13 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20190117624A1 (en) 2016-03-29 2019-04-25 Daiichi Sankyo Company, Limited Therapeutic agent for inflammatory bowel diseases
JP6925367B2 (ja) 2016-04-13 2021-08-25 ミトブリッジ，インコーポレーテッド Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法
CN113943255B (zh) * 2020-07-17 2024-08-06 深圳信立泰药业股份有限公司 一种手性3-(4-环丙基-2,5-二氧杂咪唑啉-4-基)丙酸的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6163661A (ja) * 1984-09-05 1986-04-01 Microbial Chem Res Found ヒスタジン関連化合物
US5993815A (en) * 1996-11-08 1999-11-30 University Of Vermont Methods and compositions for inhibiting the activation of thrombin-activatable fibrinolysis inhibitor (TAFI)
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds

Also Published As

Publication number Publication date
NO20030706L (no) 2003-04-15
EE200300070A (et) 2005-02-15
CA2419633A1 (en) 2002-02-21
ATE447557T1 (de) 2009-11-15
DK1311488T3 (da) 2010-01-04
DOP2001000233A (es) 2002-05-15
UY26889A1 (es) 2002-03-22
PE20020352A1 (es) 2002-05-11
EA005532B1 (ru) 2005-04-28
JP2008169224A (ja) 2008-07-24
IL153225A0 (en) 2003-07-06
EP1311488A1 (en) 2003-05-21
PA8525401A1 (es) 2002-04-25
JP4778531B2 (ja) 2011-09-21
KR20030022412A (ko) 2003-03-15
AR035580A1 (es) 2004-06-16
TNSN01126A1 (fr) 2005-11-10
OA12362A (en) 2004-04-07
BG107330A (en) 2003-06-30
MXPA03001425A (es) 2003-06-06
NZ522823A (en) 2004-11-26
AP1375A (en) 2005-03-03
HRP20030103A2 (en) 2003-04-30
IS6638A (is) 2002-11-28
ES2334101T3 (es) 2010-03-05
SV2002000602A (es) 2002-10-24
BR0113289A (pt) 2003-06-17
JP4119746B2 (ja) 2008-07-16
MA26940A1 (fr) 2004-12-20
SI1311488T1 (sl) 2010-01-29
NO20030706D0 (no) 2003-02-14
CA2419633C (en) 2011-05-10
DE60140368D1 (de) 2009-12-17
EP1311488B1 (en) 2009-11-04
PT1311488E (pt) 2009-12-30
EA200201239A1 (ru) 2003-08-28
WO2002014285A1 (en) 2002-02-21
CZ2003388A3 (cs) 2004-03-17
AP2001002250A0 (en) 2001-09-30
PL361054A1 (en) 2004-09-20
AU2001276605A1 (en) 2002-02-25
HUP0303763A2 (hu) 2004-04-28
HUP0303763A3 (en) 2004-06-28
JP2004506044A (ja) 2004-02-26
CN1443173A (zh) 2003-09-17
SK1732003A3 (en) 2004-08-03

Similar Documents

Publication Publication Date Title
CY1109693T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΙΜΙΔΑΖΟΛΙΑ ΩΣ ΑΝΑΣΤΟΛΕΙΣ TAFIa
CY1109886T1 (el) Καινοφανεις ενωσεις ως αντι-φλεγμονωδεις, ανοσοτροποποιητικοι και αντι υπερπλαστικοι παραγοντες
CY1105915T1 (el) Παραγωγα θειαζολιου για τη θepαπεια των παθησεων που σχετιζονται με τους ppar
CY1108470T1 (el) Πεπτιδια και πεπτιδομιμητες που εχουν αντι-πολλαπλασιαστικη δραστικοτητα και/ή τα οποια ενισχυουν παραγοντες ή αγωγες που προκαλουν βλαβη στο dna
YU21401A (sh) Tetrahidropiridoetri
CY1108041T1 (el) Αναστολεις της rho-κινασης
DE60309848D1 (de) Purinderivate als kinaseinhibitoren
CY1109385T1 (el) Αναστολεις γυρασης και χρησεις αυτων
CY1107475T1 (el) Αναστολεις ρο-κινασης
CL2012002380A1 (es) Compuestos derivados de bezoimidazol, inhibidores de mek; utiles en el tratamiento del cancer.(divisional solicitud cl 521-03)
CY1109656T1 (el) Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης
DE60230890D1 (de) Indolizine als kinaseproteinhemmer
ATE341537T1 (de) Dolastatin 10 derivate
CY1113314T1 (el) (3-αρυλ-πιπεραζιν-1-υλ) παραγωγα της 6,7-διαλκοξυκιναζολινης, 6,7-διαλκοξυφθαλαζινης και 6,7-διαλκοξυϊσοκινολινης
DE60121345D1 (de) Alkylierte imidazopyridinderivate
ATE386742T1 (de) Imidazonaphthyridine
CY1109992T1 (el) Παραγωγα του αλφα-αμιναμιδιου χρησιμα ως αντιφλεγμονωδη μεσα
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
ATE265455T1 (de) Tetrahydropyridoverbindungen
BR9902084A (pt) Heterociclos.
PL372769A1 (en) Cyanoguanidine prodrugs
DE60304360D1 (de) N-aryl-2-oxazolidinone und deren derivate
DE60224805D1 (de) 1-glycinyl-4-(1-methylpiperidin-4-yl)piperazine un
ATE328883T1 (de) Imidazopyridin-8-one
CY1107334T1 (el) Μεθοδοι για την αναστολη της αγγειογενεσης